PETACH TIKVA, Israel - PolyPid Ltd. (NASDAQ:PYPD), a late-stage biopharmaceutical company, announced its plan to release fourth-quarter and full-year 2023 financial results and operational highlights before the U.S. financial markets open on Wednesday, February 14, 2024. Following the release, the company will conduct a conference call and webcast at 8:30 AM Eastern Time to discuss these results and update on business operations.
PolyPid specializes in surgical outcomes improvement through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, which allows for local, controlled, and prolonged-release of therapeutics. The company's leading product candidate, D-PLEX100, is currently in a Phase 3 clinical trial aimed at preventing surgical site infections after abdominal colorectal surgeries.
In addition to D-PLEX100, PolyPid is advancing its preclinical program, OncoPLEX, targeting the treatment of solid tumors, with an initial focus on glioblastoma.
The upcoming conference call and webcast will provide investors and interested parties with an opportunity to gain insights into PolyPid's performance and strategic direction. Participants are encouraged to register for the conference call at least five minutes before it begins. For those not intending to ask questions, the company suggests listening through the webcast.
PolyPid's approach to drug delivery represents a significant part of its research and development efforts, aiming to enhance post-surgical patient outcomes with targeted and sustained medication release.
The information for this announcement is based on a press release statement by PolyPid Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.